Review Artikel: Liposom Sebagai SistemPenghantar Obat Epilepsi Melalui Jalur Intranasal
DOI:
https://doi.org/10.70608/gr88kz85Keywords:
Liposom, Sistem Penghantar Obat Inhalasi, NebulasiAbstract
Sekitar 80% dari total penderita epilepsi di seluruh dunia ditemukan di negara berkembang. Memodifiksi senyawa obat, upaya yang banyak dilakukan adalah memodifikasi bentuk sediaan dan sistem penghantaran obat. Upaya ini tidak terlepas dari peran farmasi yang memanfaatkan ilmu sains dan teknologi untuk mengatasi adanya keterbatasan pada beberapa bentuk sediaan dan sistem penghantaran obat. Salah satu sistem penghantaran obat adalah melalui teknologi inhalasi. Teknologi inhalasi dapat dikombinasikan dengan teknologi liposom untuk meningkatkan bioavaibilitas dan waktu onset yang cepat. Liposom adalah teknologi tersusun dari bahan dasar fosfatidilkolin lapisan bilayer dengan ukuran 25nm-2,5µm. Selain itu fosfatidilkolin juga merupakan surfaktan paru yang efektif untuk meningkatkan proses absorbsi obat. Sudah banyak juga review komperhensif mengembangkan liposom untuk teknologi inhalasi. Obat antiepilepsi saat ini memiliki koefesien partisi dan bioavaibilitas yang rendah. Obat anti epilepsi dengan teknologi liposom diharapkan menjadi alternative pengobatan non-invasive melalui jalur inhalasi.
Downloads
References
[1] M. Lindenberg, S. Kopp, and J. B. Dressman, “Classification of orally administered drugs on the World Health Organization Model List of Essential Medicines according to the biopharmaceutics classification system,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 58, no. 2, pp. 265–278, 2004, doi: 10.1016/j.ejpb.2004.03.001. DOI: https://doi.org/10.1016/j.ejpb.2004.03.001
[2] I. Megiddo, A. Colson, D. Chisholm, T. Dua, A. Nandi, and R. Laxminarayan, “Health and economic benefits of public financing of epilepsy treatment in India: An agent-based simulation model,” Epilepsia, vol. 57, no. 3, pp. 464–474, 2016, doi: 10.1111/epi.13294. DOI: https://doi.org/10.1111/epi.13294
[3] M. Moreira and M. Sarraguça, “How can oral paediatric formulations be improved? A challenge for the XXI century,” International Journal of Pharmaceutics, vol. 590, Art. no. 119905, 2020, doi: 10.1016/j.ijpharm.2020.119905. DOI: https://doi.org/10.1016/j.ijpharm.2020.119905
[4] F. Laffleur and V. Keckeis, “Advances in drug delivery systems: Work in progress still needed?,” International Journal of Pharmaceutics, vol. 590, Art. no. 119912, 2020, doi: 10.1016/j.ijpharm.2020.119912. DOI: https://doi.org/10.1016/j.ijpharm.2020.119912
[5] D. Cipolla, I. Gonda, and H.-K. Chan, “Liposomal formulations for inhalation,” Therapeutic Delivery, vol. 4, no. 8, pp. 1047–1072, 2013, doi: 10.4155/tde.13.71. DOI: https://doi.org/10.4155/tde.13.71
[6] N. B. Agarwal, S. Jain, D. Nagpal, N. K. Agarwal, P. K. Mediratta, and K. K. Sharma, “Liposomal formulation of curcumin attenuates seizures in different experimental models of epilepsy in mice,” Fundamental & Clinical Pharmacology, vol. 27, no. 2, pp. 169–172, 2013, doi: 10.1111/j.1472-8206.2011.01002.x. DOI: https://doi.org/10.1111/j.1472-8206.2011.01002.x
[7] X. Zhou et al., “Modulation of mononuclear phagocyte inflammatory response by liposome-encapsulated voltage gated sodium channel inhibitor ameliorates myocardial ischemia/reperfusion injury in rats,” PLOS ONE, vol. 8, no. 9, pp. 1–13, 2013, doi: 10.1371/journal.pone.0074390. DOI: https://doi.org/10.1371/journal.pone.0074390
[8] Y. S. Choi et al., “Enhanced cell survival of pH-sensitive bioenergetic nucleotide nanoparticles in energy/oxygen-depleted cells and their intranasal delivery for reduced brain infarction,” Acta Biomaterialia, vol. 41, pp. 147–160, 2016, doi: 10.1016/j.actbio.2016.05.037. DOI: https://doi.org/10.1016/j.actbio.2016.05.037
[9] D. B. Vieira and L. F. Gamarra, “Getting into the brain: Liposome-based strategies for effective drug delivery across the blood–brain barrier,” International Journal of Nanomedicine, vol. 11, pp. 5381–5414, 2016, doi: 10.2147/IJN.S117210. DOI: https://doi.org/10.2147/IJN.S117210
[10] M. Yokota, E. Tani, S. Tsubuki, I. Yamaura, I. Nakagaki, S. Hori, and T. C. Saido, “Calpain inhibitor entrapped in liposome rescues ischemic neuronal damage,” Brain Research, vol. 819, nos. 1–2, pp. 8–14, 1999, doi: 10.1016/S0006-8993(98)01334-1. DOI: https://doi.org/10.1016/S0006-8993(98)01334-1
[11] C. A. Maitz et al., “Validation and comparison of the therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes in multiple murine tumor models,” Translational Oncology, vol. 10, no. 4, pp. 686–692, 2017, doi: 10.1016/j.tranon.2017.05.003. DOI: https://doi.org/10.1016/j.tranon.2017.05.003
[12] S. Draffehn, J. Eichhorst, B. Wiesner, and M. U. Kumke, “Insight into the modification of polymeric micellar and liposomal nanocarriers by fluorescein-labeled lipids and uptake-mediating lipopeptides,” Langmuir, vol. 32, no. 27, pp. 6928–6939, 2016, doi: 10.1021/acs.langmuir.6b01487. DOI: https://doi.org/10.1021/acs.langmuir.6b01487
[13] H. Liu et al., “Label-free CEST MRI detection of citicoline-liposome drug delivery in ischemic stroke,” Theranostics, vol. 6, no. 10, pp. 1588–1600, 2016, doi: 10.7150/thno.15492. DOI: https://doi.org/10.7150/thno.15492
[14] M. Fresta and G. Puglisi, “Biological effects of CDP-choline loaded long circulating liposomes on rat cerebral post-ischemic reperfusion,” International Journal of Pharmaceutics, vol. 134, pp. 89–97, 1996, doi: 10.1016/0378-5173(95)04448-5. DOI: https://doi.org/10.1016/0378-5173(95)04448-5
[15] A. Lopalco, A. Cutrignelli, N. Denora, A. Lopedota, M. Franco, and V. Laquintana, “Transferrin functionalized liposomes loading dopamine HCl: Development and permeability studies across an in vitro model of human blood-brain barrier,” Nanomaterials, vol. 8, no. 3, Art. no. 178, 2018, doi: 10.3390/nano8030178. DOI: https://doi.org/10.3390/nano8030178
[16] Q. Lv et al., “Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome,” International Journal of Pharmaceutics, vol. 444, nos. 1–2, pp. 1–9, 2013, doi: 10.1016/j.ijpharm.2013.01.025. DOI: https://doi.org/10.1016/j.ijpharm.2013.01.025
[17] B. T. Roller, J. M. Munson, B. Brahma, P. J. Santangelo, S. B. Pai, and R. V. Bellamkonda, “Evans blue nanocarriers visually demarcate margins of invasive gliomas,” Drug Delivery and Translational Research, vol. 5, no. 2, pp. 116–124, 2015, doi: 10.1007/s13346-013-0139-x. DOI: https://doi.org/10.1007/s13346-013-0139-x
[18] K. Kakinuma, R. Tanaka, H. Takahashi, and Y. Sekihara, “Drug delivery to the brain using thermosensitive liposome and local hyperthermia,” International Journal of Hyperthermia, vol. 12, no. 1, pp. 157–165, 1996, doi: 10.3109/02656739609023698. DOI: https://doi.org/10.3109/02656739609023698
[19] S. Sofou, B. J. Kappel, J. S. Jaggi, M. R. McDevitt, D. A. Scheinberg, and G. Sgouros, “Enhanced retention of the α-particle-emitting daughters of actinium-225 by liposome carriers,” Bioconjugate Chemistry, vol. 18, no. 6, pp. 2061–2067, 2007, doi: 10.1021/bc070075t. DOI: https://doi.org/10.1021/bc070075t
[20] G. Henriksen, B. W. Schoultz, T. E. Michaelsen, S. Bruland, and R. H. Larsen, “Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides,” Nuclear Medicine and Biology, vol. 31, no. 4, pp. 441–449, 2004, doi: 10.1016/j.nucmedbio.2003.11.004. DOI: https://doi.org/10.1016/j.nucmedbio.2003.11.004
[21] L. C. G. A. I. Moreno, I. M. F. Cavalcanti, P. Satyal, N. S. Santos-Magalhães, H. M. L. Rolim, and R. M. Freitas, “Acute toxicity and anticonvulsant activity of liposomes containing nimodipine on pilocarpine-induced seizures in mice,” Neuroscience Letters, vol. 585, pp. 38–42, 2015, doi: 10.1016/j.neulet.2014.11.025. DOI: https://doi.org/10.1016/j.neulet.2014.11.025
[22] G. C. Vaz et al., “Cardiovascular and behavioral effects produced by administration of liposome-entrapped GABA into the rat central nervous system,” Neuroscience, vol. 285, pp. 60–69, 2015, doi: 10.1016/j.neuroscience.2014.10.067. DOI: https://doi.org/10.1016/j.neuroscience.2014.10.067
[23] K. Zasada et al., “One-component ultrathin multilayer films based on poly(vinyl alcohol) as stabilizing coating for phenytoin-loaded liposomes,” Colloids and Surfaces B: Biointerfaces, vol. 135, pp. 133–142, 2015. DOI: https://doi.org/10.1016/j.colsurfb.2015.07.033
[24] Y. Mohammad, R. N. Prentice, B. J. Boyd, and S. B. Rizwan, “Comparison of cubosomes and hexosomes for the delivery of phenytoin to the brain,” Journal of Colloid and Interface Science, vol. 605, pp. 146–154, 2022, doi: 10.1016/j.jcis.2021.07.070. DOI: https://doi.org/10.1016/j.jcis.2021.07.070
[25] N. Mori, A. Kurokouchi, K. Osonoe, H. Saitoh, K. Ariga, and K. Suzuki, “Liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats,” Brain Research, vol. 703, nos. 1–2, pp. 184–190, 1995, doi: 10.1016/0006-8993(95)01095-5. DOI: https://doi.org/10.1016/0006-8993(95)01095-5
[26] P. J. Quinn, “The effect of tocopherol on the structure and permeability of phosphatidylcholine liposomes,” Journal of Controlled Release, vol. 160, no. 2, pp. 158–163, 2012, doi: 10.1016/j.jconrel.2011.12.029. DOI: https://doi.org/10.1016/j.jconrel.2011.12.029
[27] Y. Qu, J. Tang, L. Liu, L. L. Song, S. Chen, and Y. Gao, “α-Tocopherol liposome loaded chitosan hydrogel to suppress oxidative stress injury in cardiomyocytes,” International Journal of Biological Macromolecules, vol. 125, pp. 1192–1202, 2019, doi: 10.1016/j.ijbiomac.2018.09.092. DOI: https://doi.org/10.1016/j.ijbiomac.2018.09.092
[28] A. Poudel, G. Gachumi, K. M. Wasan, Z. D. Bashi, A. El Aneed, and I. Badea, “Development and characterization of liposomal formulations containing phytosterols extracted from canola oil deodorizer distillate along with tocopherols as food additives,” Pharmaceutics, vol. 11, no. 4, Art. no. 185, 2019, doi: 10.3390/pharmaceutics11040185. DOI: https://doi.org/10.3390/pharmaceutics11040185
[29] G. Neunert, P. Górnaś, K. Dwiecki, A. Siger, and K. Polewski, “Synergistic and antagonistic effects between alpha-tocopherol and phenolic acids in liposome system: Spectroscopic study,” European Food Research and Technology, vol. 241, no. 6, pp. 749–757, 2015, doi: 10.1007/s00217-015-2500-4. DOI: https://doi.org/10.1007/s00217-015-2500-4
[30] V. Ravula, Y. L. Lo, Y. T. Wu, C. W. Chang, S. V. Patri, and L. F. Wang, “Arginine-tocopherol bioconjugated lipid vesicles for selective pTRAIL delivery and subsequent apoptosis induction in glioblastoma cells,” Materials Science and Engineering C, vol. 126, Art. no. 112189, 2021, doi: 10.1016/j.msec.2021.112189. DOI: https://doi.org/10.1016/j.msec.2021.112189
[31] F. Nacka, M. Cansell, P. Méléard, and N. Combe, “Incorporation of α-tocopherol in marine lipid-based liposomes: In vitro and in vivo studies,” Lipids, vol. 36, no. 12, pp. 1313–1320, 2001, doi: 10.1007/s11745-001-0846-x. DOI: https://doi.org/10.1007/s11745-001-0846-x
[32] A. K. Chakrabarti, S. Dasgupta, R. H. Gadsden, E. L. Hogan, and N. L. Banik, “Regulation of brain m calpain Ca2+ sensitivity by mixtures of membrane lipids: Activation at intracellular Ca2+ level,” Journal of Neuroscience Research, vol. 44, no. 4, pp. 374–380, 1996, doi: 10.1002/(SICI)1097-4547(19960515)44:4<374::AID-JNR9>3.0.CO;2-9. DOI: https://doi.org/10.1002/(SICI)1097-4547(19960515)44:4<374::AID-JNR9>3.0.CO;2-9
[33] L. M. Yu, Y. S. Zhu, C. Z. Xu, L. L. Zhou, Z. X. Xue, and Z. Z. Cai, “High calpain-1 expression predicts a poor clinical outcome and contributes to tumor progression in pancreatic cancer patients,” Clinical and Translational Oncology, vol. 21, no. 7, pp. 924–932, 2019, doi: 10.1007/s12094-018-02006-6. DOI: https://doi.org/10.1007/s12094-018-02006-6
[34] J. Sforzi, G. Ferrauto, S. Aime, and S. Geninatti Crich, “A simple and fast assay based on carboxyfluorescein-loaded liposome for quantitative DNA detection,” ACS Omega, vol. 5, no. 4, pp. 1764–1772, 2020, doi: 10.1021/acsomega.9b01457. DOI: https://doi.org/10.1021/acsomega.9b01457
[35] J. N. Weinstein, R. Blumenthal, and R. D. Klausner, “Carboxyfluorescein leakage assay for lipoprotein–liposome interaction,” Methods in Enzymology, vol. 128, pp. 657–668, 1986, doi: 10.1016/0076-6879(86)28098-2. DOI: https://doi.org/10.1016/0076-6879(86)28098-2
[36] Y. Shimoyama et al., “Effects of application method on skin penetration of carboxyfluorescein incorporated in liposomes,” Chemical & Pharmaceutical Bulletin (Tokyo), vol. 58, no. 3, pp. 429–431, 2010, doi: 10.1248/cpb.58.429. DOI: https://doi.org/10.1248/cpb.58.429
[37] M. Badran, K. Shalaby, and A. Al-Omrani, “Influence of the flexible liposomes on the skin deposition of a hydrophilic model drug, carboxyfluorescein: Dependency on their composition,” The Scientific World Journal, vol. 2012, pp. 1–10, 2012, doi: 10.1100/2012/134876. DOI: https://doi.org/10.1100/2012/134876
[38] R. F. Chen and J. R. Knutson, “Mechanism of fluorescence concentration quenching of carboxyfluorescein in liposomes: Energy transfer to nonfluorescent dimers,” Analytical Biochemistry, vol. 172, no. 1, pp. 61–77, 1988, doi: 10.1016/0003-2697(88)90412-5. DOI: https://doi.org/10.1016/0003-2697(88)90412-5
[39] K. Hashizaki, H. Taguchi, H. Sakai, M. Abe, Y. Saito, and N. Ogawa, “Carboxyfluorescein leakage from poly(ethylene glycol)-grafted liposomes induced by the interaction with serum,” Chemical & Pharmaceutical Bulletin (Tokyo), vol. 54, no. 1, pp. 80–84, 2006, doi: 10.1248/cpb.54.80. DOI: https://doi.org/10.1248/cpb.54.80
[40] P. Hinow, A. Radunskaya, I. Tucker, and L. Yang, “Kinetics of bile salt binding to liposomes revealed by carboxyfluorescein release and mathematical modeling,” Journal of Liposome Research, vol. 22, no. 3, pp. 237–244, 2012, doi: 10.3109/08982104.2012.675338. DOI: https://doi.org/10.3109/08982104.2012.675338
[41] R. M. Adibhatla, J. F. Hatcher, and K. Tureyen, “CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke,” Brain Research, vol. 1058, nos. 1–2, pp. 193–197, 2005, doi: 10.1016/j.brainres.2005.07.067. DOI: https://doi.org/10.1016/j.brainres.2005.07.067
[42] M. Fresta, G. Puglisi, A. M. Panico, S. Di Marco, and G. Mazzone, “CDP-choline entrapment and release from multilamellar and reverse-phase evaporation liposomes,” Drug Development and Industrial Pharmacy, vol. 19, no. 5, pp. 559–585, 1993, doi: 10.3109/03639049309062967. DOI: https://doi.org/10.3109/03639049309062967
[43] S. Duan et al., “In vivo antimalarial activity and pharmacokinetics of artelinic acid-choline derivative liposomes in rodents,” Parasitology, vol. 147, no. 1, pp. 58–64, 2020, doi: 10.1017/S0031182019001306. DOI: https://doi.org/10.1017/S0031182019001306
[44] C. Y. Lin, R. J. Li, C. Y. Huang, K. C. Wei, and P. Y. Chen, “Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery,” Journal of Drug Targeting, vol. 26, no. 4, pp. 325–332, 2018, doi: 10.1080/1061186X.2017.1379526. DOI: https://doi.org/10.1080/1061186X.2017.1379526
[45] A. Sattiraju et al., “Alpha particle enhanced blood brain/tumor barrier permeabilization in glioblastomas using integrin alpha-v beta-3–targeted liposomes,” Molecular Cancer Therapeutics, vol. 16, no. 10, pp. 2191–2200, 2017, doi: 10.1158/1535-7163.MCT-16-0907. DOI: https://doi.org/10.1158/1535-7163.MCT-16-0907
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Alhara Yuwanda (Author)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
